The availability and cost of biomarker tests can limit their widespread adoption. Some biomarker tests may require specialized equipment or expertise, making them less accessible, particularly in resource-limited settings. Biomarkers for early cancer detection should ideally allow for longitudinal monitoring to track disease progression, treatment response, and recurrence. Developing biomarkers that provide real-time and dynamic information about the disease can be challenging. Thus, along with the undisputable advantages, the applications of biomarkers for early cancer diagnosis has also certain disadvantages (Table ). It is important to note that the advantages and disadvantages of biomarkers can vary depending on the specific biomarker, cancer type, and stage of cancer. Each biomarker should be evaluated and interpreted in the context of clinical guidelines and in collaboration with healthcare professionals. Limited Sensitivity: Some biomarkers may not have high sensitivity in the early stages of cancer or for certain types of cancer. This can result in missed diagnoses or delayed detection.